{"classes":[{"categories":[{"measurements":[{"comment":"Data not available due to high censoring.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"0.7","upperLimit":"6.6","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"Time to Deterioration of Pulmonary Symptoms Measured by the NSCLC-Symptom Assessment Questionnaire (SAQ) (with Pembrolizumab)","dispersionType":"95% Confidence Interval","groups":[{"description":"160 mg Selpercatinib administered orally BID continuously in 21-day cycles.","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"Pemetrexed 500 mg/m2, IV on Day 1 Q3W plus investigator's choice of carboplatin AUC 5 (maximum dose 750 mg) IV or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.","id":"OG001","title":"Pemetrexed and Platinum With Pembrolizumab (TRT B)"}],"paramType":"MEDIAN","populationDescription":"ITT Pembrolizumab: Participants included in the ITT population who were stratified with the intent to receive pembrolizumab in the event of the control-arm assignment. Participants censored: TRT A: 99; TRT B: 47.","reportingStatus":"POSTED","timeFrame":"Baseline to Deterioration of Pulmonary Symptoms Up to 31 Months","title":"Time to Deterioration of Pulmonary Symptoms (With Pembrolizumab)","type":"SECONDARY","unitOfMeasure":"Months"}